Log in or register to see all Alerts
New HTA Decisions in Scotland
June 2020
Drug name
IMBRUVICA® (ibrutinib)
Janssen-Cilag Ltd
Decision date
Therapeutic area
Therapeutic sub area
Blood and bone marrow cancers
Not recommended
As a single agent for the treatment of adult patients with Waldenström’s macroglobulinaemia who have recieved at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.
Decision Detail
In the absence of a submission from the holder of the marketing authorisation, ibrutinib (IMBRUVICA®) is not recommended for use within NHS Scotland.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result the SMC cannot recommend its use within NHS Scotland.